R&D for Development of New Drugs for Neglected Diseases How Can India Contribte?
The focus of this paper is India. In line with TRIPS India has introduced a product patent regime in pharmaceuticals from 1 January, 2005. WIll this lead increase in resources deveoted to R and D by Indian companies for the development of new drugs more suited to the needs of India and other developing countries? Can the innovation capabilities be utilized for developing new drugs for neglected diseases? Can India contribte to lowering the cost of new drug development and make drugs more accessible?
When requesting a correction, please mention this item's handle: RePEc:ess:wpaper:id:2149. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Padma Prakash)
If references are entirely missing, you can add them using this form.